Humacyte specializes in the development and commercialization of universally implantable, bioengineered human tissues and blood vessels. Its primary commercial and clinical asset is Symvess (an Acellular Tissue Engineered Vessel, or ATEV), which is designed for vascular trauma repair, hemodialysis access, and peripheral arterial disease treatments. These bioengineered vessels serve as regenerative alternatives to synthetic grafts or harvested patient veins, minimizing immune rejection and infection risks.